Solana

Solana ROE

The Return on Equity (ROE) of Solana (HSDT) as of Oct 24, 2026 is -13.59 %. In the previous year, Return on Equity (ROE) was -1,108.78 % — a change of -98.77% (higher).

ROE

-13.59 %

YoY

-98.77%

Last updated:

In 2025, Solana's return on equity (ROE) was -13.59 %, a -98.77% increase from the -1,108.78 % ROE in the previous year.

The Solana ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-290.47 USD
Jan 1, 2019
-167.63 USD
Jan 1, 2020
-365.02 USD
Jan 1, 2021
-161.09 USD
Jan 1, 2022
-172.64 USD
Jan 1, 2023
-376.60 USD
Jan 1, 2024
-1,108.78 USD
Jan 1, 2025
-13.59 USD
The Solana ROE history
YEARROEYoY
-13.59 %-98.77%
-1,108.78 %+194.42%
-376.60 %+118.14%
-172.64 %+7.17%
-161.09 %-55.87%
-365.02 %+117.76%
-167.63 %-42.29%
-290.47 %-177.63%
374.15 %-99.12%
42,498.68 %-0.01%
42,501.31 %+6,651.70%
629.49 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Solana Stock analysis

What does Solana do? Helius Medical Technologies develops and markets the PoNS device, a portable neuromodulation stimulator for neurological wellness. The company focuses on non-invasive platform technologies that enhance the brain's healing ability. The PoNS device is authorized as a class II medical device in Canada for short-term treatment of chronic balance deficits caused by mild-to-moderate traumatic brain injury, used alongside physical therapy. It delivers non-invasive neurostimulation to the tongue to induce neuromodulation. Helius Medical Technologies targets healthcare providers and rehabilitation centers that treat patients with traumatic brain injury. The company's product is designed for use in clinical settings under professional guidance, specifically for patients requiring short-term balance deficit therapy. The PoNS device is positioned as a complementary treatment within physical therapy protocols for neurological rehabilitation. The firm's revenue model is based on the sale of the PoNS device to healthcare institutions and rehabilitation facilities. These institutions purchase the device for use in their treatment programs, leveraging its non-invasive neurostimulation technology to address balance deficits in patients with mild-to-moderate traumatic brain injury. The company's focus on neurological wellness through non-invasive solutions drives its commercial strategy. Solana is one of the most popular companies on Eulerpool.

ROE Details

Decoding Solana's Return on Equity (ROE)

Solana's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Solana's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Solana's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Solana’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Solana stock

Return on Equity (ROE) of Solana is -13.59 % in 2025.

Return on Equity (ROE) of Solana changed from -1,108.78 % to -13.59 %, representing a -98.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Solana since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Solana with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Solana

All Key Metrics — Solana